Pgiam/iStock via Getty Images
Cassava Sciences (NASDAQ:SAVA) traded higher in the premarket on Tuesday after the Alzheimer’s drug developer received its only buy rating on Wall Street as H.C. Wainwright upgraded the stock, citing a settlement the company recently reached with the SEC.
With